A bold new research collaboration, backed by a prestigious $3 million Terry Fox New Frontiers Program Project Grant, is setting out to bridge scientific fields and unlock the answer to this all-important question central to patient care. Led by Dr. Michele Ardolino, the team of investigators will seek to uncover the hidden mechanisms of how the body’s immune system, nervous system, and gut microbiome interact in cancer. Their cross-disciplinary work and innovative approach has the potential to fundamentally reshape cancer treatment.

Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive lymphoma or tumor of the brain. While ventricular brain lymphoma is even rarer, its clinical characteristics and treatment strategies remain less explored. Now, researchers have evaluated the clinical features of PCNSL lesions involving the ventricles. They found that this rare tumor type shares key features with other brain lymphomas, suggesting a unified treatment approach.

A new review in Chinese Medical Journal highlights exosomes’ role in obstructive sleep apnea (OSA)-related diseases. OSA’s intermittent hypoxia alters exosome cargo, driving cellular dysfunction linked to cardiovascular issues, diabetes, neurodegeneration, and cancer, while exosomes also show therapeutic potential.

Gynecological cancers remain a major threat to women's health, with traditional therapies often having limited effect and severe side effects. A new class of "“Magic bullets", known as Antibody-Drug Conjugates (ADCs), is now changing the game. With the first ADC for cervical cancer already approved and more in development for ovarian and uterine cancers, new hope is emerging for patients with recurrent disease. A literature review published in SCIENCE CHINA Life Sciences provides a comprehensive overview of ADCs, synthesizing existing evidence from ongoing clinical trials and preclinical studies in gynecological cancers. It examines the adverse reactions associated with ADCs and explores strategies to mitigate these adverse effects, thereby enhancing the efficacy of ADCs in treating gynecological malignancies.